Consolación Rosado1, Elena Bueno2, Carmen Felipe3, Rogelio González-Sarmiento2. 1. Department of Medicine, Molecular Medicine Unit, University of Salamanca Salamanca, Spain ; Department of Nephrology, Ávila Hospital Ávila, Spain. 2. Department of Medicine, Molecular Medicine Unit, University of Salamanca Salamanca, Spain ; IBSAL and IBMCC, University of Salamanca, CSIC and SACYL Salamanca, Spain. 3. Department of Nephrology, Ávila Hospital Ávila, Spain.
Abstract
BACKGROUND: Autosomal forms of Alport syndrome represent 20% of all patients (15% recessive and 5% dominant). They are caused by mutations in the COL4A3 and COL4A4 genes, which encode a-3 and a-4 collagen IV chains of the glomerular basement membrane, cochlea and eye. Thin basement membrane nephropathy may affect up to 1% of the population. The pattern of inheritance in the 40% of cases is the same as autosomal dominant Alport syndrome: heterozygous mutations in these genes. The aim of this study is to detect new pathogenic mutations in the COL4A4 gene in the patients previously diagnosed with autosomal Alport syndrome and thin basement membrane nephropathy in our hospital. METHODS: We conducted a clinical and genetic study in eleven patients belonging to six unrelated families with aforementioned clinical symptoms and a negative study of COL4A3 gene. The molecular study was made by conformation of sensitive gel electrophoresis (CSGE) and direct sequencing of the fragments that show an altered electrophoretic migration pattern. RESULTS: We found two pathogenic mutations, not yet described: IVS3 + 1G > C is a replacement of Guanine to Cytosine in position +1 of intron 3, in the splicing region, which leads to a pathogenic mutation. c.4267C > T; p.P1423S is a missense mutation, also considered pathogenic. We also found seven new polymorphisms. CONCLUSIONS: We describe two new pathogenic mutations, responsible for autosomal dominant Alport syndrome. The other families of the study were undiagnosed owing to problems in the method employed and the possibility of mutations in other genes, giving rise to other diseases with similar symptoms.
BACKGROUND: Autosomal forms of Alport syndrome represent 20% of all patients (15% recessive and 5% dominant). They are caused by mutations in the COL4A3 and COL4A4 genes, which encode a-3 and a-4 collagen IV chains of the glomerular basement membrane, cochlea and eye. Thin basement membrane nephropathy may affect up to 1% of the population. The pattern of inheritance in the 40% of cases is the same as autosomal dominant Alport syndrome: heterozygous mutations in these genes. The aim of this study is to detect new pathogenic mutations in the COL4A4 gene in the patients previously diagnosed with autosomal Alport syndrome and thin basement membrane nephropathy in our hospital. METHODS: We conducted a clinical and genetic study in eleven patients belonging to six unrelated families with aforementioned clinical symptoms and a negative study of COL4A3 gene. The molecular study was made by conformation of sensitive gel electrophoresis (CSGE) and direct sequencing of the fragments that show an altered electrophoretic migration pattern. RESULTS: We found two pathogenic mutations, not yet described: IVS3 + 1G > C is a replacement of Guanine to Cytosine in position +1 of intron 3, in the splicing region, which leads to a pathogenic mutation. c.4267C > T; p.P1423S is a missense mutation, also considered pathogenic. We also found seven new polymorphisms. CONCLUSIONS: We describe two new pathogenic mutations, responsible for autosomal dominant Alport syndrome. The other families of the study were undiagnosed owing to problems in the method employed and the possibility of mutations in other genes, giving rise to other diseases with similar symptoms.
Authors: Mark Buzza; Hayat Dagher; Yan Yan Wang; Diane Wilson; Jeffrey J Babon; Richard G Cotton; Judy Savige Journal: Kidney Int Date: 2003-02 Impact factor: 10.612
Authors: K E Heath; A Campos-Barros; A Toren; G Rozenfeld-Granot; L E Carlsson; J Savige; J C Denison; M C Gregory; J G White; D F Barker; A Greinacher; C J Epstein; M J Glucksman; J A Martignetti Journal: Am J Hum Genet Date: 2001-10-04 Impact factor: 11.025
Authors: H H Lemmink; W N Nillesen; T Mochizuki; C H Schröder; H G Brunner; B A van Oost; L A Monnens; H J Smeets Journal: J Clin Invest Date: 1996-09-01 Impact factor: 14.808
Authors: Daniel P Gale; Elena Goicoechea de Jorge; H Terence Cook; Rubén Martinez-Barricarte; Andreas Hadjisavvas; Adam G McLean; Charles D Pusey; Alkis Pierides; Kyriacos Kyriacou; Yiannis Athanasiou; Konstantinos Voskarides; Constantinos Deltas; Andrew Palmer; Véronique Frémeaux-Bacchi; Santiago Rodriguez de Cordoba; Patrick H Maxwell; Matthew C Pickering Journal: Lancet Date: 2010-08-25 Impact factor: 79.321
Authors: Michael Zeisberg; Mona Khurana; Velidi H Rao; Dominic Cosgrove; Jean-Philippe Rougier; Michelle C Werner; Charles F Shield; Zena Werb; Raghu Kalluri Journal: PLoS Med Date: 2006-03-07 Impact factor: 11.069
Authors: Jeffrey H Miner; Colin Baigent; Frances Flinter; Oliver Gross; Parminder Judge; Clifford E Kashtan; Sharon Lagas; Judith Savige; Dave Blatt; Jie Ding; Daniel P Gale; Julian P Midgley; Sue Povey; Marco Prunotto; Daniel Renault; Jules Skelding; A Neil Turner; Susie Gear Journal: Kidney Int Date: 2014-07-02 Impact factor: 10.612
Authors: Petar Šenjug; Tamara Nikuševa Martić; Marija Šenjug Perica; Maja Oroz; Matija Horaček; Martin Ćuk; Slaven Abdović; Danica Galešić Ljubanović Journal: Croat Med J Date: 2019-10-31 Impact factor: 1.351